The effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2019 Results assessing study of apatinib combined with vinorelbine in advanced non-small cell lung cancer published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 28 Jan 2019 Phase has been changed from phase1 to phase2.
- 28 Jan 2019 Planned number of patients changed from 32 to 30.